KOREA PHARMA Co., Ltd. (KOSDAQ:032300)

KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 126.74 billion. The enterprise value is 138.14 billion.

Market Cap	126.74B
Enterprise Value	138.14B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 29, 2025

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 0.14% in one year.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	63.38%
Owned by Institutions (%)	0.01%
Float	3.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.45
PB Ratio	1.84
P/TBV Ratio	1.94
P/FCF Ratio	n/a
P/OCF Ratio	47.17
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 69.02, with an EV/FCF ratio of -8.15.

EV / Earnings	-52.32
EV / Sales	1.58
EV / EBITDA	69.02
EV / EBIT	n/a
EV / FCF	-8.15

Financial Position

The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.57.

Current Ratio	1.14
Quick Ratio	0.74
Debt / Equity	0.57
Debt / EBITDA	17.08
Debt / FCF	-2.30
Interest Coverage	-0.25

Financial Efficiency

Return on equity (ROE) is -3.77% and return on invested capital (ROIC) is -1.14%.

Return on Equity (ROE)	-3.77%
Return on Assets (ROA)	-0.46%
Return on Invested Capital (ROIC)	-1.14%
Return on Capital Employed (ROCE)	-1.27%
Weighted Average Cost of Capital (WACC)	8.27%
Revenue Per Employee	653.74M
Profits Per Employee	-19.70M
Employee Count	134
Asset Turnover	0.73
Inventory Turnover	2.74

Taxes

Income Tax	-1.88B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.18% in the last 52 weeks. The beta is 0.79, so KOREA PHARMA's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	-23.18%
50-Day Moving Average	12,436.40
200-Day Moving Average	13,701.75
Relative Strength Index (RSI)	44.35
Average Volume (20 Days)	24,627

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 87.60 billion and -2.64 billion in losses. Loss per share was -242.00.

Revenue	87.60B
Gross Profit	31.37B
Operating Income	-887.33M
Pretax Income	-4.52B
Net Income	-2.64B
EBITDA	2.28B
EBIT	-887.33M
Loss Per Share	-242.00

Balance Sheet

The company has 27.53 billion in cash and 38.94 billion in debt, with a net cash position of -11.41 billion or -1,045.92 per share.

Cash & Cash Equivalents	27.53B
Total Debt	38.94B
Net Cash	-11.41B
Net Cash Per Share	-1,045.92
Equity (Book Value)	68.79B
Book Value Per Share	6,297.40
Working Capital	7.80B

Cash Flow

In the last 12 months, operating cash flow was 2.69 billion and capital expenditures -19.64 billion, giving a free cash flow of -16.96 billion.

Operating Cash Flow	2.69B
Capital Expenditures	-19.64B
Depreciation & Amortization	3.17B
Net Borrowing	11.28B
Free Cash Flow	-16.96B
FCF Per Share	-1,554.73

Margins

Gross margin is 35.81%, with operating and profit margins of -1.01% and -3.01%.

Gross Margin	35.81%
Operating Margin	-1.01%
Pretax Margin	-5.16%
Profit Margin	-3.01%
EBITDA Margin	2.60%
EBIT Margin	-1.01%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.45%.

Dividend Per Share	50.00
Dividend Yield	0.45%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.14%
Shareholder Yield	0.31%
Earnings Yield	-2.08%
FCF Yield	-13.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 2.62 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.62
Piotroski F-Score	3